Effect of Factor XIII Val34Leu on α2-antiplasmin Incorporation into Fibrin

V. Schroder; H. P. Kohler

doi:10.1055/s-0037-1614189

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 84(06): 1128-1130
DOI: 10.1055/s-0037-1614189

Letters to the Editor

Schattauer GmbH

Effect of Factor XIII Val34Leu on α₂-antiplasmin Incorporation into Fibrin

V. Schroder

¹Thrombosis Research Laboratory, Department of Clinical Research, University Hospital of Bern, Switzerland

,

H. P. Kohler

¹Thrombosis Research Laboratory, Department of Clinical Research, University Hospital of Bern, Switzerland

References
1 Kohler HP, Stickland MH, Ossei-Gerning N, Carter C, Mikkola H. Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
2 Wartiovaara U, Perola M, Mikkola H, Töttcrman K, Savolainen V, Penttilä A, Grant PJ, Tikkancn MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FX1II Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999; 142: 295-300.
3 Elbaz A, Poirier O, Canapie S, Chédru F, Cambien F, Amarenco P. The association between the Val34Lea polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
4 Kohler HP, Furers TS, Gram PJ. Prevalence of three common polymorphisms in the A-subnnit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 1999; 81: 511-5.
5 Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
6 Kohler HP, Ariëns RAS, Whitaker P, Grant PJ. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb Haemost 1998; 80: 704.
7 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-70.
8 Ariëns RAS, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-2016.
9 Tamaki T, Aoki N. Cross-linking of a2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981; 661: 280-6.
10 Song YC, Sheng DQ, Taubenfeld SM, Matsueda GR. A microliter assay for factor XIII using fibrinogen and biotinylcadaverine as substrates. Anal Biochem 1994; 223: 88-92.
11 Sakata Y, Aoki N. Cross-linking of α₂-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
12 Francis RT, McDonagh J, Mann XG. Factor V is a substrate for the trans amidase factor Xllla. J Biol Chem 1986; 261: 9787-92.
13 Kimura S, Aoki N. Cross-linking site in fibrinogen for α₂-plasmin inhibitor. JBioIChem 1986; 261: 15591-5.
14 Mosher DF, Schad PE, Kleinman HK. Cross-linking of fibronectin to collagen by blood coagulation factor Xllla. J Clin Invest 1979; 64: 781-7.
15 Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin activable fibrinolysis inhibitor, is a substrate for transglutaminases. J Biol Chem 1998; 273: 27220-4.